
|Videos|January 22, 2015
Dr. Edith Perez on Etirinotecan Pegol for HER2-Negative Breast Cancer
Author(s)Edith A. Perez, MD,
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.
Advertisement
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.
The BEACON trial (BrEAst Cancer Outcomes with NKTR-102) is an important study for refractory HER2-negative breast cancer, says Perez. It looks at the new compound etirinotecan pegol (NKTR-102), a long-acting topoisomerase-1 inhibitor designed for prolonged tumor cell exposure, in comparison to physicians’ choice of treatment.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5



































